Friday, October 28, 2005—Not a good week for entry inhibitors. First GSK’s aplaviroc went kaput, and today, Schering-Plough announced that the company is discontinuing one of its Phase II trials of entry inhibitor-hopeful vicriviroc. This particular trial looked at vicriviroc’s use in tandem with Combivir. While aplaviroc dropped out because it proved dangerous for liver enzyme levels, the vicriviroc/Combivir combo simply failed to lower HIV in the blood as much as Combivir plus Sustiva.